Back to Search Start Over

Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia.

Authors :
Ceolin V
Cenna R
Resente F
Spadea M
Fagioli F
Bertorello N
Source :
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2022 Mar; Vol. 39 (2), pp. 187-192. Date of Electronic Publication: 2021 Aug 09.
Publication Year :
2022

Abstract

A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.

Details

Language :
English
ISSN :
1521-0669
Volume :
39
Issue :
2
Database :
MEDLINE
Journal :
Pediatric hematology and oncology
Publication Type :
Report
Accession number :
34369835
Full Text :
https://doi.org/10.1080/08880018.2021.1959691